Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, first-in-class PD-1/VEGF bispecific ...

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

As we continue developing new therapies for lung cancer, and increasingly give them in sequence, evaluating the benefit of one line of therapy will by necessity become more focused on time-limited ...

Piqray plus Faslodex significantly improved PFS in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast ...

A low prognostic nutritional index may indicate a reduced response to ICIs due to diminished hepatic function and systemic inflammation.

Topline data were announced from a phase 3 trial evaluating varegacestat in patients with progressing desmoid tumors.

Italian investigators sought to determine if combining R-CHOP plus ibrutinib followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC ...

The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...